| Title |
Gilteritinib maintenance after allogeneic stem cell transplantation for FLT3 mutated acute myeloid leukemia / |
| Authors |
Žučenka, Andrius ; Vasilevska, Dominika ; Daukėlaitė, Guoda ; Trociukas, Igoris ; Pečeliūnas, Valdas ; Pileckytė, Regina ; Griškevičius, Laimonas |
| DOI |
10.1097/01.HS9.0000969204.07443.aa |
| Full Text |
|
| Is Part of |
HemaSphere: 28th Congress of the European Hematology Association EHA2023, June 8 - 15, Frankfurt, 2023 : abstract book.. Philadelphia : Ovid Technologies (Wolters Kluwer Health). 2023, vol. 7, suppl. 3, p. 1013-1014.. eISSN 2572-9241 |
| Keywords [eng] |
AML ; Allo-SCT ; FLT3 ; maintenance |
| Abstract [eng] |
A proportion of FLT3m AML patients remain in prolonged CRs on Gilteritinib maintenance after alloSCT despite prior exposure to Midostaurin, Gilteritinib and Venetoclax. Conversion from positive MRD to negative MRD was confirmed in several cases. Relapses post-Gilteritinib maintenance were enriched with RAS pathway mutations and clinically relevant clonal evolution such as loss of FLT3m or gain of BCR-ABL1. The toxicity of Gilteritinib was manageable. |
| Published |
Philadelphia : Ovid Technologies (Wolters Kluwer Health) |
| Type |
Conference paper |
| Language |
English |
| Publication date |
2023 |
| CC license |
|
